s
Tutte le prime pagine di oggi su Giornalone.it
EUROPEAN COMMISSION APPROVES AMGEN’S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
13-02-2026, 00:00
– (Immediapress) – First and Only CD19-Targeted Therapy Approved in Europe for Adults with anti-AChR+ and anti-MuSK+ gMG UPLIZNA Demonstrates Durable Disease Control with Twice-Yearly Dosing* THOUSAND OAKS, Calif., Feb. 12, 2026 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the European Commission (EC) has approved UPLIZNA® (inebilizumab) as an add-on treatment to standard therapy for adults […] L'articolo EUROPEAN COMMISSION APPROVES AMGEN’S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS proviene da La Ragione.
CONTINUA A LEGGERE
11
0
0